Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for Treating Inclusion Body Myositis
NCT06536166Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in inclusion body myositis (IBM), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2025; status: recruiting.
02
Drugs
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT06536166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536166.